Description
XOFIGO (RA-223 DICHLORIDE INJECTION): MOD TO DECREASE AND CLOSE OUT
Base award description: XOFIGO (RA-223 DICHLORIDE INJECTION)
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2017-10-01+$241,875= $241,875
- Mod P000012018-08-17+$49,456= $291,331
- Mod P000022019-04-24-$4,089= $287,242
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2017-10-01 | +$241,875 | $241,875 | XOFIGO (RA-223 DICHLORIDE INJECTION) |
| Mod P00001· EXERCISE AN OPTION | 2018-08-17 | +$49,456 | $291,331 | XOFIGO (RA-223 DICHLORIDE INJECTION): MOD TO INCREASE FUNDING |
| Mod P00002· CLOSE OUT | 2019-04-24 | −$4,089 | $287,242 | XOFIGO (RA-223 DICHLORIDE INJECTION): MOD TO DECREASE AND CLOSE OUT |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V1EVGCK7XES8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25626N0492 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $386,860 | FY2026 |
| 36C26226F0163 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $181,386 | FY2026 |
| 36C26026F0086 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $80,663 | FY2026 |
| 36C26126N0199 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $101,567 | FY2026 |
| 36C25626N0126 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $214,783 | FY2026 |
| 36E79725A0028 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26026F0379 | COSETTE PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $3,466 | FY2026 |
| 36C26026P0671 | MCKESSON PLASMA AND BIOLOGICS LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $18,262 | FY2026 |
| 36C26026F0349 | AGIOS PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $73,080 | FY2026 |
| 36C26026F0306 | BRACCO DIAGNOSTICS INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $337,422 | FY2026 |
| 36C26026F0298 | PROGENICS PHARMACEUTICALS INC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $469,134 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26018F2504_3600_V797P2202D_3600 · retrieved 2026-09-26.